CN101883567B - 二氨基吩噻嗪的治疗用途 - Google Patents

二氨基吩噻嗪的治疗用途 Download PDF

Info

Publication number
CN101883567B
CN101883567B CN2008801190788A CN200880119078A CN101883567B CN 101883567 B CN101883567 B CN 101883567B CN 2008801190788 A CN2008801190788 A CN 2008801190788A CN 200880119078 A CN200880119078 A CN 200880119078A CN 101883567 B CN101883567 B CN 101883567B
Authority
CN
China
Prior art keywords
daptz
compound
mtc
dose
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801190788A
Other languages
English (en)
Chinese (zh)
Other versions
CN101883567A (zh
Inventor
克劳德·M·维奇克
戴蒙·J·维奇克
约翰·M·D·斯托里
查尔斯·R·哈林顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of CN101883567A publication Critical patent/CN101883567A/zh
Application granted granted Critical
Publication of CN101883567B publication Critical patent/CN101883567B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008801190788A 2007-10-03 2008-10-01 二氨基吩噻嗪的治疗用途 Active CN101883567B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96054407P 2007-10-03 2007-10-03
US60/960,544 2007-10-03
PCT/GB2008/003315 WO2009044127A1 (en) 2007-10-03 2008-10-01 Therapeutic use of diaminophenothiazines

Publications (2)

Publication Number Publication Date
CN101883567A CN101883567A (zh) 2010-11-10
CN101883567B true CN101883567B (zh) 2012-12-26

Family

ID=40220337

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801190788A Active CN101883567B (zh) 2007-10-03 2008-10-01 二氨基吩噻嗪的治疗用途

Country Status (16)

Country Link
US (3) US9149481B2 (enExample)
EP (2) EP2954932B1 (enExample)
JP (1) JP5592261B2 (enExample)
CN (1) CN101883567B (enExample)
AU (1) AU2008306688B2 (enExample)
BR (1) BRPI0818182B1 (enExample)
CA (2) CA3027974C (enExample)
DK (2) DK2954932T3 (enExample)
ES (2) ES2701089T3 (enExample)
HR (1) HRP20151006T1 (enExample)
HU (1) HUE025199T2 (enExample)
MY (1) MY161656A (enExample)
PL (2) PL2205245T3 (enExample)
PT (2) PT2205245E (enExample)
SI (2) SI2205245T1 (enExample)
WO (1) WO2009044127A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109384741B (zh) 2006-03-29 2023-01-06 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
SI2205245T1 (sl) * 2007-10-03 2015-10-30 Wista Laboratories Ltd. Terapevtska uporaba diaminofenotiazinov
US8785434B2 (en) 2010-04-30 2014-07-22 Prosetta Antiviral Inc. Antiviral compounds
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
US9192611B2 (en) 2010-11-30 2015-11-24 Wista Laboratories Ltd. Formulations comprising methylthioninium chloride
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
EA025033B1 (ru) * 2011-02-11 2016-11-30 Уиста Лэборэтэриз Лтд. Диаминиевые соли фенотиазина и их применение
CN102690244A (zh) * 2011-03-22 2012-09-26 中国科学院上海生命科学研究院 调节α-突触核蛋白积聚的物质及其制药用途
US20130315825A1 (en) * 2012-05-03 2013-11-28 Washington University Tricyclic heteroaromatic compounds as alpha-synuclein ligands
CN103864717B (zh) * 2014-04-04 2015-11-11 山东理工大学 一种针状亚甲基白晶体的制备方法
CN103923036B (zh) * 2014-04-24 2015-09-16 山东理工大学 一种棒状亚甲基蓝晶体的制备方法
CN105541756B (zh) * 2015-12-17 2018-02-09 陕西方舟制药有限公司 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法
AU2017301966B2 (en) 2016-07-25 2022-09-22 TauRx Therapeutics Management Ltd Administration and dosage of diaminophenothiazines
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
EP3826639B1 (en) 2018-07-26 2024-08-21 WisTa Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations
CN113874078B (zh) 2019-04-05 2025-05-06 Tauc3生物制品有限公司 抗tauc3抗体及其应用
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CN111956245A (zh) * 2020-08-27 2020-11-20 复旦大学附属肿瘤医院 术后认知功能障碍预防评估方法，系统和装置
EP4531863A1 (en) 2022-05-31 2025-04-09 WisTa Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
EP4590306A1 (en) 2022-09-21 2025-07-30 Yin Sze Loh Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases
WO2024163665A1 (en) * 2023-01-31 2024-08-08 Unlearn.AI, Inc. Systems and methods for prognostic covariate adjustment in logistic regression for randomized controlled trial design

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055720A2 (en) * 2001-01-15 2002-07-18 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
DE4140192C2 (de) * 1991-12-05 1996-02-29 Alfatec Pharma Gmbh Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) * 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US7410965B2 (en) * 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
US7790881B2 (en) * 2004-09-23 2010-09-07 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
US20070116757A1 (en) * 2005-11-08 2007-05-24 Collegium Pharmaceutical, Inc. Methylene Blue Derivatives
PL2004155T3 (pl) * 2006-03-29 2018-08-31 Wista Laboratories Ltd. Inhibitory agregacji białek
CN109384741B (zh) * 2006-03-29 2023-01-06 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
HUE030621T2 (en) * 2006-07-11 2017-05-29 Wista Lab Ltd Methods for the synthesis and / or purification of diaminophenothiazinium compounds
CN101820884B (zh) * 2007-06-19 2013-08-28 维斯塔实验室有限公司 用于治疗轻度认知缺损的吩噻嗪化合物
SI2205245T1 (sl) * 2007-10-03 2015-10-30 Wista Laboratories Ltd. Terapevtska uporaba diaminofenotiazinov

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055720A2 (en) * 2001-01-15 2002-07-18 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease

Also Published As

Publication number Publication date
JP5592261B2 (ja) 2014-09-17
EP2205245B1 (en) 2015-06-24
HRP20151006T1 (hr) 2015-10-23
SI2205245T1 (sl) 2015-10-30
US20100290986A1 (en) 2010-11-18
MY161656A (en) 2017-04-28
PT2954932T (pt) 2018-12-12
ES2546819T3 (es) 2015-09-28
US20190151329A1 (en) 2019-05-23
CA2701075A1 (en) 2009-04-09
EP2205245A1 (en) 2010-07-14
JP2010540606A (ja) 2010-12-24
EP2954932B1 (en) 2018-09-19
SI2954932T1 (sl) 2019-01-31
AU2008306688A1 (en) 2009-04-09
CA3027974C (en) 2022-03-15
CA2701075C (en) 2019-02-12
BRPI0818182A2 (pt) 2020-06-23
US9149481B2 (en) 2015-10-06
US20160030444A1 (en) 2016-02-04
EP2954932A1 (en) 2015-12-16
HK1211889A1 (en) 2016-06-03
PL2954932T3 (pl) 2019-04-30
HK1140675A1 (en) 2010-10-22
DK2954932T3 (en) 2018-12-17
ES2701089T3 (es) 2019-02-20
DK2205245T3 (en) 2015-09-28
CA3027974A1 (en) 2009-04-09
US10188658B2 (en) 2019-01-29
AU2008306688B2 (en) 2014-05-22
CN101883567A (zh) 2010-11-10
BRPI0818182B1 (pt) 2021-10-19
PL2205245T3 (pl) 2015-12-31
WO2009044127A1 (en) 2009-04-09
PT2205245E (pt) 2015-10-13
HUE025199T2 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
CN101883567B (zh) 二氨基吩噻嗪的治疗用途
JP5520043B2 (ja) ３，７−ジアミノ−１０ｈ−フェノチアジン塩およびその使用
ES2659030T3 (es) Compuestos de tioninio y su uso
JP7073330B2 (ja) ジアミノフェノチアジンの投与及び投与量
RS55237B1 (sr) Fenotiazin diaminijum soli i njihova primena
KR20190045273A (ko) 치매 치료
CA3078732A1 (en) C5ar inhibitor reduction of urinary scd163
CN118105392A (zh) 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
JP5563559B2 (ja) ２−アミノ−３−スルホニル−テトラヒドロピラゾロ［１，５−ａ］ピリド−ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、調製のための方法及びその使用
HK1140675B (en) Therapeutic use of diaminophenothiazines
HK1211889B (en) Therapeutic use of diaminophenothiazines
JP2025527188A (ja) Ｎｌｒｐ３阻害剤の投与計画
HK40025020A (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant